Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

BACKGROUND: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing pain. We aimed to explore the body composition an...

Descripción completa

Detalles Bibliográficos
Autores principales: Brener, Avivit, Lebenthal, Yael, Cleper, Roxana, Kapusta, Livia, Zeitlin, Leonid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970173/
https://www.ncbi.nlm.nih.gov/pubmed/33796255
http://dx.doi.org/10.1177/20420188211001150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970173/
https://www.ncbi.nlm.nih.gov/pubmed/33796255
http://dx.doi.org/10.1177/20420188211001150

Ejemplares similares